Skip to main content

47 - References

References

618 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 5 References

  1. Murphy TK, et al. Practice parameter for the assessment and treatment of children and adolescents with tic disorders. J Am Acad Child Adolesc Psychiatry 2013; 52:­1341–­1359.
  2. Pringsheim T, et al. European Society for the Study of Tourette Syndrome 2022 criteria for clinical diagnosis of functional tic-­like behaviours: international consensus from experts in tic disorders. Eur J Neurol 2023; 30:­902–­910.
  3. Szejko N, et al. European clinical guidelines for Tourette syndrome and other tic ­disorders –­ version 2.0. Part I: assessment. Eur Child Adolesc Psychiatry 2022; 31:­383–­402.
  4. McGuire JF, et al. A meta-­analysis of behavior therapy for Tourette syndrome. J Psychiatr Res 2014; 50:­106–­112.
  5. Rizzo R, et al. A randomized controlled trial comparing behavioral, educational, and pharmacological treatments in youths with chronic tic disorder or Tourette syndrome. Front Psychiatry 2018; 9:100.
  6. Andrén P, et al. European clinical guidelines for Tourette syndrome and other tic ­disorders –­ ­version 2.0. Part II: psychological interventions. Eur Child Adolesc Psychiatry 2022; 31:­403–­423.
  7. Patel H, et al. Use of complementary and alternative medicine in children with Tourette syndrome. J Child Neurol 2020; 35:­512–­516.
  8. Kumar A, et  al. A comprehensive review of Tourette syndrome and complementary alternative medicine. Curr Dev Disord Rep 2018; 5:­95–­100.
  9. Farhat LC, et al. Comparative efficacy, tolerability, and acceptability of pharmacological interventions for the treatment of children, adolescents, and young adults with Tourette’s syndrome: a systematic review and network meta-­analysis. Lancet Child Adolesc Health 2023; 7:­112–­126.
  10. Goetz CG, et al. Clonidine and Gilles de la Tourette’s syndrome: double-­blind study using objective rating methods. Ann Neurol 1987; 21:­307–­310.
  11. Leckman JF, et al. Clonidine treatment of Gilles de la Tourette’s syndrome. Arch Gen Psychiatry 1991; 48:­324–­328.
  12. Tourette’s Syndrome Study Group. Treatment of ADHD in children with tics: a randomized controlled trial. Neurology 2002; 58:­527–­536.
  13. Du YS, et al. Randomized double-­blind multicentre placebo-­controlled clinical trial of the clonidine adhesive patch for the treatment of tic disorders. Aust N Z J Psychiatry 2008; 42:­807–­813.
  14. Hedderick EF, et al. Double-­blind, crossover study of clonidine and levetiracetam in Tourette syndrome. Pediatr Neurol 2009; 40:­420–­425.
  15. Song PP, et al. The efficacy and tolerability of the clonidine transdermal patch in the treatment for children with tic disorders: a prospective, open, single-­group, self-­controlled study. Front Neurol 2017; 8:32.
  16. Scahill L, et al. A placebo-­controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am J Psychiatry 2001; 158:­1067–­1074.
  17. Cummings DD, et al. Neuropsychiatric effects of guanfacine in children with mild Tourette syndrome: a pilot study. Clin Neuropharmacol 2002; 25:­325–­332.
  18. Osland ST, et al. Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders. Cochrane Database Syst Rev 2018; 6:CD007990.
  19. Pringsheim T, et al. Pimozide for tics in Tourette’s syndrome. Cochrane Database Syst Rev 2009; 2009:CD006996.
  20. Roessner V, et al. European clinical guidelines for Tourette syndrome and other tic ­disorders –­ version 2.0. Part III: pharmacological treatment. Eur Child Adolesc Psychiatry 2022; 31:­425–­441.
  21. Yoo HK, et al. An open-­label study of the efficacy and tolerability of aripiprazole for children and adolescents with tic disorders. J Clin Psychiatry 2007; 68:­1088–­1093.
  22. Yoo HK, et al. A multicenter, randomized, double-­blind, placebo-­controlled study of aripiprazole in children and adolescents with Tourette’s disorder. J Clin Psychiatry 2013; 74:­e772–­e780.
  23. Sallee F, et al. Randomized, double-­blind, placebo-­controlled trial demonstrates the efficacy and safety of oral aripiprazole for the treatment of Tourette’s disorder in children and adolescents. J Child Adolesc Psychopharmacol 2017; 27:­771–­781.
  24. Davies L, et al. A case series of patients with Tourette’s syndrome in the United Kingdom treated with aripiprazole. Hum Psychopharmacol 2006; 21:­447–­453.
  25. Seo WS, et  al. Aripiprazole treatment of children and adolescents with Tourette disorder or chronic tic disorder. J Child Adolesc Psychopharmacol 2008; 18:­197–­205.
  26. Murphy TK, et  al. Open label aripiprazole in the treatment of youth with tic disorders. J Child Adolesc Psychopharmacol 2009; 19:­441–­447.
  27. Wenzel C, et  al. Aripiprazole for the treatment of Tourette syndrome: a case series of 100 patients. J Clin Psychopharmacol 2012; 32:­548–­550.
  28. Rizzo R, et al. Metabolic effects of aripiprazole and pimozide in children with Tourette syndrome. Pediatr Neurol 2012; 47:­419–­422.
  29. Liu Y, et al. Effectiveness and tolerability of aripiprazole in children and adolescents with Tourette’s disorder: a meta-­analysis. J Child Adolesc Psychopharmacol 2016; 26:­436–­441.
  30. Wang S, et al. The efficacy and safety of aripiprazole for tic disorders in children and adolescents: a systematic review and meta-­analysis. Psychiatry Res 2017; 254:­24–­32.
  31. Ghanizadeh A. Twice-­weekly aripiprazole for treating children and adolescents with tic disorder, a randomized controlled clinical trial. Ann Gen Psychiatry 2016; 15:21.
  32. Tao D, et al. Randomized controlled clinical trial comparing the efficacy and tolerability of aripiprazole and sodium valproate in the treatment of Tourette syndrome. Ann Gen Psychiatry 2019; 18:24.
  33. Scahill L, et al. A placebo-­controlled trial of risperidone in Tourette syndrome. Neurology 2003; 60:­1130–­1135.

Prescribing in children and adolescents CHAPTER 5 34. Gaffney GR, et al. Risperidone versus clonidine in the treatment of children and adolescents with Tourette’s syndrome. J Am Acad Child Adolesc Psychiatry 2002; 41:­330–­336. 35. Onofrj M, et al. Olanzapine in severe Gilles de la Tourette syndrome: a 52-­week double-­blind cross-­over study vs. low-­dose pimozide. J Neurol 2000; 247:­443–­446. 36. Robertson MM, et al. Management of Gilles de la Tourette syndrome using sulpiride. Clin Neuropharmacol 1990; 13:­229–­235. 37. Sallee FR, et  al. Ziprasidone treatment of children and adolescents with Tourette’s syndrome: a pilot study. J Am Acad Child Adolesc Psychiatry 2000; 39:­292–­299. 38. Mukaddes NM, et al. Quetiapine treatment of children and adolescents with Tourette’s disorder. J Child Adolesc Psychopharmacol 2003; 13:­295–­299. 39. Budman CL, et al. An open-­label study of the treatment efficacy of olanzapine for Tourette’s disorder. J Clin Psychiatry 2001; 62:­290–­294. 40. McCracken JT, et al. Effectiveness and tolerability of open label olanzapine in children and adolescents with Tourette syndrome. J Child Adolesc Psychopharmacol 2008; 18:­501–­508. 41. Caine ED, et al. The trial use of clozapine for abnormal involuntary movement disorders. Am J Psychiatry 1979; 136:­317–­320. 42. Roessner V, et al. Pharmacological treatment of tic disorders and Tourette syndrome. Neuropharmacology 2013; 68:­143–­149. 43. Singer HS, et  al. Baclofen treatment in Tourette syndrome: a double-­blind, placebo-­controlled, crossover trial. Neurology 2001; 56:­599–­604. 44. Silver AA, et al. Transdermal nicotine and haloperidol in Tourette’s disorder: a double-­blind placebo-­controlled study. J Clin Psychiatry 2001; 62:­707–­714. 45. Peterson BS, et al. A double-­blind, placebo-­controlled, crossover trial of an antiandrogen in the treatment of Tourette’s syndrome. J Clin Psychopharmacol 1998; 18:­324–­331. 46. Nicolson R, et al. A randomized, double-­blind, placebo-­controlled trial of metoclopramide for the treatment of Tourette’s disorder. J Am Acad Child Adolesc Psychiatry 2005; 44:­640–­646. 47. Yang CS, et al. Topiramate for Tourette’s syndrome in children: a meta-­analysis. Pediatr Neurol 2013; 49:­344–­350. 48. Porta M, et al. Tourette’s syndrome and role of tetrabenazine: review and personal experience. Clin Drug Invest 2008; 28:­443–­459. 49. Gilbert DL, et al. Ecopipam, a D1 receptor antagonist, for treatment of Tourette syndrome in children: a randomized, placebo-­controlled crossover study. Mov Disord 2018; 33:­1272–­1280. 50. Gilbert DL, et al. Ecopipam for Tourette syndrome: a randomized trial. Pediatrics 2023; 151:e2022059574. 51. Chou CY, et al. Emerging therapies and recent advances for Tourette syndrome. Heliyon 2023; 9:e12874. 52. Sandyk R. Clomiphene citrate in Tourette’s syndrome. Int J Neurosci 1988; 43:­103–­106. 53. Shapira NA, et al. Novel use of tramadol hydrochloride in the treatment of Tourette’s syndrome. J Clin Psychiatry 1997; 58:­174–­175. 54. Bonnier C, et al. Ketanserin treatment of Tourette’s syndrome in children. Am J Psychiatry 1999; 156:­1122–­1123. 55. Izmir M, et al. Cyproterone acetate treatment of Tourette’s syndrome. Can J Psychiatry 1999; 44:­710–­711. 56. Awaad Y, et al. Use of levetiracetam to treat tics in children and adolescents with Tourette syndrome. Mov Disord 2005; 20:­714–­718. 57. Hienert M, et al. Pregabalin in Tourette’s syndrome: a case series. Am J Psychiatry 2016; 173:­1242–­1243. 58. Sandyk R, et al. Marijuana and Tourette’s syndrome. J Clin Psychopharmacol 1988; 8:­444–­445. 59. Curtis A, et al. Cannabinoids for Tourette’s syndrome. Cochrane Database Syst Rev 2009; 2009:CD006565. 60. Artukoglu BB, et al. The potential of cannabinoid-­based treatments in Tourette syndrome. CNS Drugs 2019; 33:­417–­430. 61. Pandey S, et al. Botulinum toxin for motor and phonic tics in Tourette’s syndrome. Cochrane Database Syst Rev 2018; 1:CD012285. 62. Martino D, et  al. The PANDAS subgroup of tic disorders and childhood-­onset obsessive-­compulsive disorder. J Psychosom Res 2009; 67:­547–­557. 63. Chang K, et al. Clinical evaluation of youth with pediatric acute-­onset neuropsychiatric syndrome (PANS): recommendations from the 2013 PANS Consensus Conference. J Child Adolesc Psychopharmacol 2015; 25:­3–­13.

No comments to display

Back to top